Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost View cart “Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost” has been added to your cart. €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Cerebrospinal fluid dynamics and primary open-angle glaucoma €15.00 Add to cart Biomechanics and the aqueous humor outflow pathway €15.00 Add to cart IOP homeostasis ? Why most people do not ever develop glaucoma €15.00 Add to cart The microenvironment of subconjunctival tissue after glaucoma filtration surgery €15.00 Add to cart